Sequencing of cytomegalovirus UL97 gene for genotypic antiviral resistance testing

N. S. Lurain, A. Weinberg, C. S. Crumpacker, Sunwen Chou

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

The widespread use of ganciclovir (GCV) to treat cytomegalovirus (CMV) infections in immunosuppressed patients has led to the development of drug resistance. Phenotypic assays for CMV drug resistance are presently too time-consuming to be therapeutically useful. To support the development of genotypic assays for GCV resistance, the complete sequences of the UL97 phosphotransferase genes in 28 phenotypically GCV-sensitive CMV clinical isolates were determined. The gene was found to be highly conserved, with nucleotide sequence identity among strains ranging from 98.6 to 100% and amino acid sequence identity of >99%. Primers for a genotypic assay were designed to amplify codons 400 to 707, because all known UL97 mutations conferring drug resistance occur at three sites within this region. This part of the UL97 gene was amplified from over 50 clinical isolates, and two sequencing reactions for the coding strand were successfully used to identify GCV resistance mutations. This genotypic assay can be performed in 48 h using genomic DNA extracted from cell monolayers at very low levels of virus infectivity, thus rapidly providing therapeutically useful results.

Original languageEnglish (US)
Pages (from-to)2775-2780
Number of pages6
JournalAntimicrobial Agents and Chemotherapy
Volume45
Issue number10
DOIs
StatePublished - 2001
Externally publishedYes

Fingerprint

Ganciclovir
Cytomegalovirus
Antiviral Agents
Drug Resistance
Genes
Mutation
Cytomegalovirus Infections
Codon
Amino Acid Sequence
Phosphotransferases
Viruses
DNA

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Sequencing of cytomegalovirus UL97 gene for genotypic antiviral resistance testing. / Lurain, N. S.; Weinberg, A.; Crumpacker, C. S.; Chou, Sunwen.

In: Antimicrobial Agents and Chemotherapy, Vol. 45, No. 10, 2001, p. 2775-2780.

Research output: Contribution to journalArticle

Lurain, N. S. ; Weinberg, A. ; Crumpacker, C. S. ; Chou, Sunwen. / Sequencing of cytomegalovirus UL97 gene for genotypic antiviral resistance testing. In: Antimicrobial Agents and Chemotherapy. 2001 ; Vol. 45, No. 10. pp. 2775-2780.
@article{d29c3020cb404a34826637f0f8a54b20,
title = "Sequencing of cytomegalovirus UL97 gene for genotypic antiviral resistance testing",
abstract = "The widespread use of ganciclovir (GCV) to treat cytomegalovirus (CMV) infections in immunosuppressed patients has led to the development of drug resistance. Phenotypic assays for CMV drug resistance are presently too time-consuming to be therapeutically useful. To support the development of genotypic assays for GCV resistance, the complete sequences of the UL97 phosphotransferase genes in 28 phenotypically GCV-sensitive CMV clinical isolates were determined. The gene was found to be highly conserved, with nucleotide sequence identity among strains ranging from 98.6 to 100{\%} and amino acid sequence identity of >99{\%}. Primers for a genotypic assay were designed to amplify codons 400 to 707, because all known UL97 mutations conferring drug resistance occur at three sites within this region. This part of the UL97 gene was amplified from over 50 clinical isolates, and two sequencing reactions for the coding strand were successfully used to identify GCV resistance mutations. This genotypic assay can be performed in 48 h using genomic DNA extracted from cell monolayers at very low levels of virus infectivity, thus rapidly providing therapeutically useful results.",
author = "Lurain, {N. S.} and A. Weinberg and Crumpacker, {C. S.} and Sunwen Chou",
year = "2001",
doi = "10.1128/AAC.45.10.2775-2780.2001",
language = "English (US)",
volume = "45",
pages = "2775--2780",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "10",

}

TY - JOUR

T1 - Sequencing of cytomegalovirus UL97 gene for genotypic antiviral resistance testing

AU - Lurain, N. S.

AU - Weinberg, A.

AU - Crumpacker, C. S.

AU - Chou, Sunwen

PY - 2001

Y1 - 2001

N2 - The widespread use of ganciclovir (GCV) to treat cytomegalovirus (CMV) infections in immunosuppressed patients has led to the development of drug resistance. Phenotypic assays for CMV drug resistance are presently too time-consuming to be therapeutically useful. To support the development of genotypic assays for GCV resistance, the complete sequences of the UL97 phosphotransferase genes in 28 phenotypically GCV-sensitive CMV clinical isolates were determined. The gene was found to be highly conserved, with nucleotide sequence identity among strains ranging from 98.6 to 100% and amino acid sequence identity of >99%. Primers for a genotypic assay were designed to amplify codons 400 to 707, because all known UL97 mutations conferring drug resistance occur at three sites within this region. This part of the UL97 gene was amplified from over 50 clinical isolates, and two sequencing reactions for the coding strand were successfully used to identify GCV resistance mutations. This genotypic assay can be performed in 48 h using genomic DNA extracted from cell monolayers at very low levels of virus infectivity, thus rapidly providing therapeutically useful results.

AB - The widespread use of ganciclovir (GCV) to treat cytomegalovirus (CMV) infections in immunosuppressed patients has led to the development of drug resistance. Phenotypic assays for CMV drug resistance are presently too time-consuming to be therapeutically useful. To support the development of genotypic assays for GCV resistance, the complete sequences of the UL97 phosphotransferase genes in 28 phenotypically GCV-sensitive CMV clinical isolates were determined. The gene was found to be highly conserved, with nucleotide sequence identity among strains ranging from 98.6 to 100% and amino acid sequence identity of >99%. Primers for a genotypic assay were designed to amplify codons 400 to 707, because all known UL97 mutations conferring drug resistance occur at three sites within this region. This part of the UL97 gene was amplified from over 50 clinical isolates, and two sequencing reactions for the coding strand were successfully used to identify GCV resistance mutations. This genotypic assay can be performed in 48 h using genomic DNA extracted from cell monolayers at very low levels of virus infectivity, thus rapidly providing therapeutically useful results.

UR - http://www.scopus.com/inward/record.url?scp=0034812453&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034812453&partnerID=8YFLogxK

U2 - 10.1128/AAC.45.10.2775-2780.2001

DO - 10.1128/AAC.45.10.2775-2780.2001

M3 - Article

C2 - 11557468

AN - SCOPUS:0034812453

VL - 45

SP - 2775

EP - 2780

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 10

ER -